Navigation Links
BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies
Date:7/14/2011

NOVATO, Calif., July 14, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.  A Phase 1/2 trial for BMN 673 for the treatment of patients with solid tumors was initiated in January 2011 and is ongoing.

"We are excited to be at the forefront of studying the potential benefit of PARP inhibitors in hematological malignancies," said Hank Fuchs, M.D., Chief Medical Officer of BioMarin.  "Our approach to the development of our PARP inhibitor is to identify tumor mutations that are more susceptible to treatment with BMN 673 and to target subgroups based on the genetic basis of the disease.  We are committed to the advancement of our pipeline and look forward to many clinical milestones over the next 18 months."

This Phase 1 trial is a two-arm, open-label dose escalation study to determine the maximum tolerated dose and to assess the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of once daily, oral BMN 673 in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL).  The study will enroll approximately 80 patients across multiple sites in the U.S. and UK.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMarin Announces Roll-Out of National PKU Registry
2. BioMarin to Present at the Citi Biotech Day
3. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
4. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
5. BioMarin Corrects Information Included in Bloomberg Article
6. BioMarin Announces Third Quarter 2008 Financial Results
7. BioMarin to Present at the Credit Suisse Healthcare Conference
8. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
9. BioMarin to Present at the Piper Jaffray Healthcare Conference
10. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
11. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 26, 2014 The Alliance ... a survey of European physicians at the "1 ... and Biological Therapies" at the Spanish Ministry of ... by EuropaBio and the Spanish Bioindustry Association (ASEBIO), ... physicians from Spanish oncology and rheumatology societies, representatives ...
(Date:11/26/2014)... Whitehouse Laboratories is pleased to announce ... (New Jersey) Chamber of Commerce as a member. ... in the North Jersey area, offers Whitehouse Laboratories ... clients in the pharmaceutical and biotechnology areas that ... enables Whitehouse Laboratories a higher level of visibility ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 The Pittcon ... its official conference and exposition mobile app, ... free download in the App Store for iOS and ... valuable resource tool before, during and after the event. ... details on exhibiting companies, technical sessions, Conferee Networking sessions ...
(Date:11/26/2014)... PLAINSBORO, N.J. and WILMINGTON, DE (PRWEB) November 26, 2014 ... the 2nd Annual MPN Heroes recognition reception on December ... Society of Hematology’s annual meeting. The MPN Heroes event ... significant contributions in the field of myeloproliferative neoplasms (MPNs). ... TV show "Nashville," will discuss his family's cancer journey ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3Pittcon Releases 2015 Mobile App 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4
... September 2 According to a new,market research ... MarketsandMarkets ( http://www.marketsandmarkets.com ), the global,biosimilars market is ... recording,a CAGR of 89.1% from 2009 to 2014. ... to reduce the costs of blockbuster,biopharmaceuticals has created ...
... , WALTHAM, Mass., Sept. 2 Repligen Corporation ... and Chief Executive Officer, Walter C. Herlihy, Ph.D., will present at ... 9th, 2009 at 2:25 p.m. EDT at the New York Palace ... webcast of the presentation will be available via Repligen,s website at ...
... of the problem: In a swarm of small fish it ... found in the microcosm of atoms and molecules, whose behavior ... control over single electrons in a bunch, ultrashort light pulses ... Max Planck Institute of Quantum Optics (MPQ) in Garching and ...
Cached Biology Technology:MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014 2MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014 3Repligen to Present at the Rodman & Renshaw 11th Annual Healthcare Conference Wednesday, September 9th, 2:25 p.m. EDT 2Repligen to Present at the Rodman & Renshaw 11th Annual Healthcare Conference Wednesday, September 9th, 2:25 p.m. EDT 3Laser pulses control single electrons in complex molecules 2Laser pulses control single electrons in complex molecules 3
(Date:11/4/2014)... at the right time might actually help boost a ... help in understanding animal populations, pest control and managing ... the journal Trends in Ecology and Evolution , ... the kind of positive population effect an overall species ... on the size and developmental stage of the creatures ...
(Date:11/4/2014)... about the way our bodies are assembled during early ... they are supposed to become a nerve or a ... correct place and alignment? Researchers at the University of ... a new study, UM researchers describe the signaling systems ... at the head-trunk region. Their discovery may have important ...
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2The inside story: How the brain and skull stay together 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... NEW YORK , Aug. 15, 2013   ... authentication solutions, announced today the appointment of Michael ...  Fiorito,s appointment reinforces the adoption and expansion of ... enterprise market. In this role, Fiorito ...
... German researchers have identified four biomarkers that correctly determine ... accurate prediction of patient outcomes. Their results are published ... Molecular Diagnostics . Current prognosticators of bladder cancer, ... foci, have limited usefulness for clinicians since they do ...
... who often recall their dreams respond more strongly to their ... mysteries of human cognition. It is still not fully known ... them. A major difficulty for studying dreams is that they ... Ruby and colleagues from the Lyon Neuroscience Research Center chose ...
Cached Biology News:EyeLock Appoints Michael Fiorito Vice President of Enterprise Accounts 2MicroRNAs have diagnostic and prognostic potential in urinary bladder cancer 2Frontiers news briefs: Aug. 13 2Frontiers news briefs: Aug. 13 3